Connect with us

Health

FDA Approves First Drug to Treat Rare Metabolic Disorder – PharmiWeb.com

SILVER SPRING, Md., Nov. 23, 2020 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria…

Published

on

ADVERTISEMENT

SILVER SPRING, Md., Nov. 23, 2020 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria type 1 (PH1), a rare genetic disorder. This approval is a cumulation of the work of experts and community members coordinated by the Oxalosis & Hyperoxaluria Foundation and the Kidney Health Initiative.    
“The approval of Oxlumo represents a great triumph of community involvement to address a rare disease. It is a result of…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

‘They were freaking out’: meet the people treating NHS workers for trauma – The Guardian
post featured image
UK chief scientist says new virus variant may be more deadly – Egypt Independent – Egypt Independent